Cyprotex
Emma Wilson is a Scientist II at Cyprotex since July 2019, contributing to the drug metabolism group. Prior to this role, Emma held positions in ADME screening at York Bioanalytical Solutions and worked as a freelance pharmaceutical market analyst at Wilson Research & Insights LTD, specializing in extensive market analysis reports. Emma's experience includes a lengthy tenure as a Senior Scientist at GlaxoSmithKline from January 2003 to January 2017, where responsibilities encompassed the development and optimization of whole cell compound screening assays for various small molecule medicines across multiple target classes. Emma holds a BSc honours degree in Microbial Science from The University of Huddersfield, completed in 2002.
This person is not in any offices
Cyprotex
Founded in 1999, Cyprotex (www.cyprotex.com) has grown to become an industry leader in in vitro and in silico ADME-Tox. The company, with sites in the UK and USA, was acquired by Evotec (www.evotec.com) in 2016. The Evotec Group offer expert support from early discovery through to clinical development. * High-throughput ADME screening * Customised ADME assays * In silico ADME predictive modeling * In vitro toxicology